Recent ASCCP guidelines 2025, and difference between 2019 and 2025 guidelines. Provide detailed overview using tables,
Reading File
Searching the Web
ASCCP 2025 cervical cancer screening guidelines updates
Searching PubMed
ASCCP cervical cancer screening guidelines 2025
Reading Web Page
ASCCP 2025 guidelines cervical cancer screening management changes updates
Searching the Web
ASCCP 2025 vs 2019 guidelines differences HPV self-collection extended genotyping p16 Ki67
Finding Sources
Reading Web Page
ASCCP 2025 guidelines self-collection extended genotyping p16 Ki67 dual stain changes from 2019
Finding Sources
I now have comprehensive information to compile the detailed overview. Let me synthesize everything into a thorough, well-structured response.
ASCCP Guidelines: 2019 vs. 2025 - Detailed Comparative Overview
The 2019 ASCCP Risk-Based Management Consensus Guidelines introduced a paradigm shift from result-based to risk-based management. Since 2019, the ASCCP's Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee has published three major updates (2024-2025), collectively representing what is referred to as the 2025 ASCCP framework. The clinical management recommendations were last updated June 10, 2025.
KEY FRAMEWORK COMPARISON
| Feature | 2019 Guidelines | 2025 Updates |
|---|---|---|
| Core paradigm | Risk-based management using current + prior results | Retained; extended to new technologies |
| Primary HPV screening | Acceptable for age ≥25 | Retained; expanded triage options added |
| Genotyping used | Limited: HPV 16, HPV 18, and HR pooled (12 types) | Extended: HPV 16, 18, 31, 33, 45, 52, 58 individually |
| Triage biomarker | Cytology (Pap) only | p16/Ki67 Dual Stain now a formal triage option |
| Specimen collection | Clinician-collected only | Self-collected vaginal specimens now endorsed |
| Immunosuppressed patients | Basic guidance | Expanded to include SOT, ESRD on dialysis, SLE |
| Screening cessation | Age 65 with adequate prior screening | Shared decision-making approach added |
| App integration | Yes (risk tables) | Updated: Dual Stain results now included |
1. SELF-COLLECTED VAGINAL SPECIMENS FOR HPV TESTING (NEW in 2025)
Published: J Low Genit Tract Dis. 2025;29(2):144-151 - Wentzensen et al.
| Aspect | 2019 Guideline | 2025 Update |
|---|---|---|
| Specimen type | Clinician-collected only | Self-collected vaginal specimens now endorsed |
| Rationale | Not addressed | Improves accessibility, reduces barriers to screening |
| Equivalence | N/A | Self-collected samples shown equivalent to clinician-collected for primary HPV testing |
| Population target | Standard population | Especially beneficial for underserved, unscreened, or rarely screened individuals |
| Test used | Clinician-collected HPV test | FDA-approved HPV tests validated for self-collection |
| Follow-up after positive | N/A | Same management algorithm as clinician-collected positive result |
2. EXTENDED HPV GENOTYPING (NEW in 2025)
Published: J Low Genit Tract Dis. 2025;29(2):134-143 - Massad et al.
| HPV Type(s) | 2019 Management | 2025 Extended Genotyping Management |
|---|---|---|
| HPV 16 | Immediate colposcopy | Immediate colposcopy (retained) |
| HPV 18 | Immediate colposcopy | Immediate colposcopy (retained) |
| HPV 45 | Pooled with "other HR" | Now identified separately - colposcopy preferred |
| HPV 31, 33 | Pooled "other HR" - cytology triage | Higher individual risk identified - expedited management |
| HPV 52, 58 | Pooled "other HR" - cytology triage | Lower individual risk stratification possible |
| Pooled HR-HPV (12 types) | Single category for non-16/18 | Individual type-specific risk stratification now available |
| Post-treatment setting | Standard protocol | 2019 guidelines retained (insufficient data to change) |
| Post-colposcopy (no high-grade) | Limited data used | Extended genotyping can now guide management |
| ASCCP App | Limited genotyping integrated | Extended genotyping NOT yet in app - clinicians use published tables |
Key principle: Extended genotyping provides greater risk stratification than pooled HPV testing. HPV-type-specific CIN3+ risk estimates now allow more individualized management.
3. p16/Ki67 DUAL STAIN (DS) (NEW in 2024, incorporated 2025)
Published: J Low Genit Tract Dis. 2024;28:124-130 - Clarke et al.
| Aspect | Pre-2024 | 2024/2025 Update |
|---|---|---|
| Biomarker | Not in guidelines | p16 (tumor suppressor - reflects HPV oncogene activity) + Ki-67 (cell proliferation marker) |
| Significance | N/A | Both positive in same cell = strongly associated with CIN3+ |
| FDA approval | N/A | FDA-approved 2020 for cytology samples from HPV+ patients |
| Use scenario | Not applicable | Triage of HPV+ results (screening and follow-up of low-grade abnormalities) |
| DS positive result | N/A | Colposcopy recommended |
| DS negative result | N/A | Repeat in 1 year |
| App integration | N/A | Dual Stain results now included in ASCCP app |
| Combined with extended genotyping | N/A | Tables available for genotype + DS combined management |
| Post-treatment | N/A | NOT used post-treatment (all HPV+ post-treatment = colposcopy regardless of DS) |
4. CORE RISK-BASED MANAGEMENT THRESHOLDS (2019, Retained in 2025)
| CIN3+ Risk | Recommended Action |
|---|---|
| ≥60% | Treatment preferred (can treat without biopsy) |
| 25-59% | Colposcopy + biopsy required |
| 4-24% | Colposcopy acceptable |
| <4% | 1-year surveillance (no immediate colposcopy) |
| <0.55% (HPV-) | Return to 5-year routine screening |
5. SCREENING STRATEGIES SUPPORTED (2019 and 2025)
| Strategy | Age Range | Interval | Notes |
|---|---|---|---|
| Primary HPV testing | ≥25 years | Every 5 years | Preferred by ACS; ASCCP-endorsed |
| Co-testing (HPV + Pap) | ≥30 years | Every 5 years | Acceptable option |
| Cytology alone (Pap) | ≥21 years | Every 3 years | Still acceptable; less sensitive |
| Self-collected HPV | ≥25 years | Every 5 years | NEW 2025 - same intervals as clinician-collected |
6. MANAGEMENT OF SPECIFIC RESULTS - 2019 vs 2025
| Clinical Scenario | 2019 Management | 2025 Update |
|---|---|---|
| HPV 16 positive, any cytology | Immediate colposcopy | Retained |
| HPV 18 positive, any cytology | Immediate colposcopy | Retained |
| HPV 45 positive | Pooled HR management | Colposcopy preferred (higher individual risk recognized) |
| HPV positive, cytology NILM | 1-year follow-up | Option to use Dual Stain: DS+ = colposcopy; DS- = 1 year |
| HPV positive, ASCUS | Colposcopy or 1-year follow-up per risk | Dual Stain triage now acceptable |
| HPV positive, LSIL | Colposcopy (most scenarios) | Extended genotyping helps stratify risk further |
| HPV positive, HSIL | Colposcopy | 2019 guidelines retained (no change) |
| Post-treatment HPV+ | Colposcopy regardless | Retained - no extended genotyping or DS changes here |
| Unsatisfactory cytology | Repeat in 2-4 months | No change |
7. SPECIAL POPULATIONS - 2025 UPDATES
| Population | 2019 Coverage | 2025 Update |
|---|---|---|
| HIV-positive | Follow CDC HIV guidelines | Retained; endorsed for SOT and ESRD patients |
| Solid organ transplant (SOT) | Limited guidance | Now explicitly: follow CDC HIV cervical cancer screening guidelines |
| ESRD on renal dialysis | Not addressed | NEW 2025: Elevated HPV/SIL/CC risk confirmed; follow CDC HIV guidelines |
| Systemic Lupus Erythematosus (SLE) | Not addressed | NEW 2025: Elevated risk regardless of immunosuppressant use; follow CDC HIV guidelines |
| Immunocompromised general | General guidance | Expanded; 3-dose HPV vaccine series recommended ages 9-26; shared decision-making ages 27-45 |
| Pregnant patients | Manage per standard risk tables | No significant change |
| Post-hysterectomy | Vaginal cuff screening per history | No change |
8. HPV VACCINATION GUIDANCE (2025 Context)
| Aspect | Recommendation |
|---|---|
| Routine vaccination | Ages 9-26 years |
| Shared decision-making | Ages 27-45 years |
| Immunosuppressed (SOT, ESRD, SLE) | 3-dose series strongly encouraged within standard age recommendations |
| Screening after vaccination | Same intervals as unvaccinated - NO change to screening protocol |
9. COLPOSCOPY STANDARDS (2017, Referenced in 2025)
These remain in force alongside 2025 updates:
| Colposcopy Feature | Standard |
|---|---|
| Biopsy deferral | Acceptable if no lesions seen, cytology <HSIL, HPV type not 16/18/45 |
| Normal findings | Can defer biopsy under above conditions |
| Abnormal findings | Biopsy of highest-grade impression lesion required |
| ECC (endocervical curettage) | Recommended in specific scenarios per 2017 standards |
| Reporting | Includes: transformation zone type, normal findings, abnormal findings, misc findings, colposcopic impression |
10. GUIDELINE HIERARCHY AND TERMINOLOGY (Unchanged)
| Term | Meaning |
|---|---|
| Recommended | Only appropriate approach |
| Preferred | Best option when multiple acceptable |
| Acceptable | Alternative when preferred not feasible |
| Not recommended | Should not be used |
| Strength | Meaning |
|---|---|
| A | Strong recommendation, high confidence |
| B | Moderate recommendation |
| C | Weak/conditional recommendation |
| D | Against |
| E | Insufficient evidence |
SUMMARY OF WHAT'S NEW IN 2025 vs. 2019
| Category | 2019 Only | Added by 2025 |
|---|---|---|
| Specimen collection | Clinician only | Self-collection endorsed |
| Triage biomarker | Cytology only | p16/Ki67 Dual Stain |
| Genotyping | Limited (16, 18, pooled HR) | Extended (individual type 31, 33, 45, 52, 58) |
| App features | Risk tables | + Dual Stain results integrated |
| Special populations | HIV | + SOT, ESRD on dialysis, SLE |
| Screening cessation | Age 65 rule | + Shared decision-making |
| Posttreatment | Standard | 2019 retained (no new data) |
| Post-colposcopy (no high-grade) | Limited | Extended genotyping can guide management |
Key references:
- ASCCP Management Guidelines App (last updated June 10, 2025)
- Wentzensen N et al. Self-Collected Vaginal Specimens for HPV Testing. J Low Genit Tract Dis. 2025;29(2):144-151
- Massad LS et al. Applying Results of Extended Genotyping... J Low Genit Tract Dis. 2025;29(2):134-143
- Clarke MA et al. Recommendations for Use of p16/Ki67 Dual Stain. J Low Genit Tract Dis. 2024;28:124-130
- Perkins RB et al. 2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023. J Low Genit Tract Dis. 2024;28:3-6
- Moscicki et al. Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women. J Low Genit Tract Dis. 2025;29(2):163-177
Clinical note: The ASCCP now operates under a rolling "Enduring Guidelines" model rather than single large consensus updates. Clinicians should check app.asccp.org for the most current risk tables, as recommendations for individual clinical scenarios may continue to update as new data emerge.
This is a shared conversation. Sign in to Orris to start your own chat.